Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 1
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for noopur grade
Your search for Noopur Ghade retrieved no results
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.
Treon SP, Gustine J, Meid K, Yang G, Xu L, Liu X, Demos M, Kofides A, Tsakmaklis N, Chen JG, Munshi M, Chan G, Dubeau T, Raje N, Yee A, O'Donnell E, Hunter ZR, Castillo JJ. Treon SP, et al. J Clin Oncol. 2018 Sep 20;36(27):2755-2761. doi: 10.1200/JCO.2018.78.6426. Epub 2018 Jul 25. J Clin Oncol. 2018. PMID: 30044692 Clinical Trial.
The 18-month, estimated progression-free survival is 92% (95% CI, 73% to 98%). All patients are alive. Grade 2/3 treatment-related toxicities in > 5% of patients included arthralgia (7%), bruising (7%), neutropenia (7%), upper respiratory tract infection (7%), urinary t …
The 18-month, estimated progression-free survival is 92% (95% CI, 73% to 98%). All patients are alive. Grade 2/3 treatment-related to …
BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study.
Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC, Keedy V, Bielle F, Hofheinz RD, Joly F, Blay JY, Chau I, Puzanov I, Raje NS, Wolf J, DeAngelis LM, Makrutzki M, Riehl T, Pitcher B, Baselga J, Hyman DM. Kaley T, et al. J Clin Oncol. 2018 Dec 10;36(35):3477-3484. doi: 10.1200/JCO.2018.78.9990. Epub 2018 Oct 23. J Clin Oncol. 2018. PMID: 30351999 Free PMC article. Clinical Trial.
RESULTS: Twenty-four patients (median age, 32 years; 18 female and six male patients) with glioma, including malignant diffuse glioma (n = 11; six glioblastoma and five anaplastic astrocytoma), PXA (n = 7), anaplastic ganglioglioma (n = 3), pilocytic astrocytoma (n = 2), and high …
RESULTS: Twenty-four patients (median age, 32 years; 18 female and six male patients) with glioma, including malignant diffuse glioma (n = 1 …
A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
Alsina M, Landgren O, Raje N, Niesvizky R, Bensinger WI, Berdeja JG, Kovacsovics T, Vesole DH, Fang B, Kimball AS, Siegel DS. Alsina M, et al. Am J Hematol. 2021 Feb 1;96(2):226-233. doi: 10.1002/ajh.26041. Epub 2020 Dec 15. Am J Hematol. 2021. PMID: 33125764 Free PMC article. Clinical Trial.
Results are presented for the carfilzomib 56 mg/m(2) NDMM dose-expansion arm (n = 33). The grade 3 treatment-emergent AE (TEAE) rate was 63.6%. Twenty-five patients underwent stem cell collection; 18 proceeded to auto stem cell transplant, and five resumed KRd on study aft …
Results are presented for the carfilzomib 56 mg/m(2) NDMM dose-expansion arm (n = 33). The grade 3 treatment-emergent AE (TEAE) rate …
Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study.
Biran N, Siegel D, Berdeja JG, Raje N, Cornell RF, Alsina M, Kovacsovics T, Fang B, Kimball AS, Landgren O. Biran N, et al. Am J Hematol. 2019 Jul;94(7):794-802. doi: 10.1002/ajh.25498. Epub 2019 May 13. Am J Hematol. 2019. PMID: 31021005 Free PMC article. Clinical Trial.
Median carfilzomib dose was 53.2 mg/m(2) (56-mg/m(2) group) and 62.4 mg/m(2) (70-mg/m(2) group). Grade 3 AE rates were 70.0% (56 mg/m(2) ) and 69.6% (70 mg/m(2) ). ...
Median carfilzomib dose was 53.2 mg/m(2) (56-mg/m(2) group) and 62.4 mg/m(2) (70-mg/m(2) group). Grade 3 AE rates were 70.0% (56 mg/m …